International Clinical Trial: A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128199) titled 'A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection' on Aug. 11.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Taiho Oncology, Inc.

Condition: NSCLC, Stage IB NSCLC, Stage IIIA

Intervention: Drug: Cisplatin Drug: Carboplatin Drug: Pemetrexed Drug: TAS6417

Recruitment Status: Not recruiting

Phase: Phase 3

Date of...